2025-05-14 07:30
Infant Bacterial Therapeutics (IBT) to present results of “The Connection Study” at ESPGHAN 2025 in Helsinki
Infant Bacterial Therapeutics (IBT) is pleased to announce that results from its pivotal Phase III trial, The Connection Study, will be presented at the...
2025-05-08 17:45
Annual General Meeting of Infant Bacterial Therapeutics
At the Annual General Meeting of Infant Bacterial Therapeutics AB (publ) on May 8, 2025, among other things, the following was resolved: ContactsStaffan...
In accordance with the agreement reached with the FDA on 19 December 2024, IBT has today submitted the Clinical Study Report (CSR) for ‘The Connection...
Message from CEO The US Food and Drug Administration (FDA) has granted IBP-9414 “Breakthrough Therapy Designation.” This means that the FDA...
2025-04-24 07:20
Infant Bacterial Therapeutics (IBT) to Present Results of “The Connection Study” at PAS 2025 in Honolulu
Infant Bacterial Therapeutics (IBT) is pleased to announce that results from its pivotal Phase III trial, “The Connection Study,” will be presented...
2025-04-07 09:40
Notice of Annual General Meeting of Infant Bacterial Therapeutics
Infant Bacterial Therapeutics AB (publ), Reg. No. 556873-8586, with its registered office in Stockholm, gives notice of the Annual General Meeting to be...
The U.S. Food and Drug Administration (FDA) has granted a Breakthrough Therapy designation for IBP-9414’s potential to reduce gastrointestinal-related...
The Annual Report including Corporate Governance Report for 2024 is available on IBT´s website, www.ibtherapeutics.com under the section "Investors...
2025-02-13 08:30
Infant Bacterial Therapeutics AB (publ) Year-end report January 1 – December 31, 2024
Message from the CEO The scientific literature suggests that benign bacteria of the type found in IBT's drug product IBP-9414 can positively affect the...
2024-12-20 16:33
IBT Continues Development of Drug Candidate IBP-9414
IBT received results in August from the largest ever randomized clinical trial in premature infants. During the fall, IBT has continued to review the phase...